Biotech

Harpoon’s IPO Spears $76M as Prostate Cancer Drug Continues Testing

Cancer immunotherapy developer Harpoon Therapeutics is the latest biotech to enter the public markets, raising approximately $76 million in an initial public offering.

South San Francisco, CA-based Harpoon offered 5.4 million shares Thursday evening priced at $14 each, which was the midpoint of the range that the company had targeted. Harpoon shares are expected to begin trading on the Nasdaq Friday under the stock symbol “HARP.”

Harpoon develops immunotherapies that direct the T cells of a patient to target and kill cancer cells. In its prospectus, Harpoon calls its drugs “T cell engagers”— engineered proteins that target cells that have… Read more »


https://xconomy.com/san-francisco/2019/02/07/harpoons-ipo-spears-76m-as-prostate-cancer-drug-continues-testing/

Advertisements
READ  Cancer Immunotherapy Biotech Raises €34M on Nasdaq Stockholm

Leave a Reply